Waters (NYSE:WAT) Stock Unloaded Rep. Thomas H. Kean, Jr.

Key Points

• Representative Thomas H. Kean Jr. disclosed a sale of Waters shares valued between $1,001 and $15,000 on March 10 in his "KEAN FAMILY PARTNERSHIP" account.
• Waters reported a slight quarterly EPS beat ($4.53 vs. $4.50) with revenue up 6.9% year-over-year and set FY2026 guidance of 14.300–14.500 EPS (Q1 guidance 2.250–2.350 EPS).
• Analyst sentiment is mixed but generally favorable—consensus is a "Moderate Buy" with a $388.22 price target—while insiders remain active (Director Wei Jiang bought 500 shares) and institutional ownership is about 94%.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Waters Corporation NYSE: WAT. In a filing disclosed on April 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Waters stock on March 10th. The trade occurred in the Representative's "KEAN FAMILY PARTNERSHIP" account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Amcor NYSE: AMCR on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Linde NASDAQ: LIN on 3/26/2026.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 3/26/2026.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 3/26/2026.
• Sold $1,001 - $15,000 in shares of First Citizens BancShares NASDAQ: FCNCA on 3/26/2026.
• Sold $15,001 - $50,000 in shares of Chubb NYSE: CB on 3/26/2026.
• Sold $15,001 - $50,000 in shares of S&P Global NYSE: SPGI on 3/26/2026.
• Purchased $1,001 - $15,000 in shares of Linde NASDAQ: LIN on 2/18/2026.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 2/13/2026.
• Purchased $1,001 - $15,000 in shares of First Citizens BancShares NASDAQ: FCNCA on 2/5/2026.

Waters Trading Up 2.0%

Waters stock opened at $331.29 on Wednesday. Waters Corporation has a 52-week low of $275.05 and a 52-week high of $414.15. The company has a quick ratio of 1.27, a current ratio of 1.73 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $32.52 billion, a price-to-earnings ratio of 30.76, a PEG ratio of 2.06 and a beta of 1.20. The firm has a 50-day moving average price of $315.14 and a two-hundred day moving average price of $352.42.

Waters (NYSE:WAT - Get Free Report) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, beating the consensus estimate of $4.50 by $0.03. The company had revenue of $932.36 million for the quarter, compared to analyst estimates of $928.17 million. Waters had a net margin of 20.30% and a return on equity of 34.79%. Waters's revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the business earned $4.10 earnings per share. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Sell-side analysts expect that Waters Corporation will post 12.86 earnings per share for the current year.

Insider Activity

In other Waters news, Director Wei Jiang bought 500 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were acquired at an average cost of $289.46 per share, for a total transaction of $144,730.00. Following the acquisition, the director directly owned 3,441 shares of the company's stock, valued at $996,031.86. This trade represents a 17.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 0.82% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

WAT has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft cut their target price on Waters from $370.00 to $330.00 and set a "hold" rating on the stock in a research note on Wednesday, March 25th. Robert W. Baird set a $363.00 price target on Waters in a report on Tuesday, February 10th. UBS Group reduced their price objective on shares of Waters from $370.00 to $330.00 and set a "neutral" rating for the company in a report on Monday. Barclays initiated coverage on shares of Waters in a research report on Tuesday, February 10th. They issued an "overweight" rating and a $400.00 target price for the company. Finally, Evercore raised shares of Waters from an "in-line" rating to an "outperform" rating and set a $350.00 price target for the company in a research note on Monday, April 6th. Three investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $388.22.

Institutional Trading of Waters

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Waters by 3.3% during the third quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier's stock valued at $2,295,612,000 after buying an additional 246,128 shares in the last quarter. Fundsmith LLP raised its position in Waters by 9.6% in the third quarter. Fundsmith LLP now owns 3,955,498 shares of the medical instruments supplier's stock worth $1,185,898,000 after acquiring an additional 347,091 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Waters by 44.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,689,693 shares of the medical instruments supplier's stock worth $806,397,000 after acquiring an additional 825,723 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Waters by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier's stock valued at $602,921,000 after acquiring an additional 8,590 shares during the last quarter. Finally, Mawer Investment Management Ltd. boosted its position in shares of Waters by 225.5% during the 3rd quarter. Mawer Investment Management Ltd. now owns 1,551,010 shares of the medical instruments supplier's stock valued at $465,008,000 after purchasing an additional 1,074,449 shares in the last quarter. Institutional investors own 94.01% of the company's stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.